US5120649A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Photodynamic inactivation of viruses in blood cell-containing compositions
Assignee: New York Blood Center
•
Filing: 1990-05-15
•
Granted: 1992-06-09
•
Expires: 2010-05-15
Abstract
Abstract The present invention concerns a method of inactivating extracelluar lipid enveloped human pathogenic virus or intracelular human pathogenic virus in a blood cell-containing composition without incurring substantial disruption or inactivation of cells, comprising contacting a cell-containing composition having ≧1×10 9 cells/ml and containing infectious virus with a virucidally effective amount of at least one photoreactive compound having an absorption maximum of ≧630 nm, light and an oxidizer to substantially inactivate the virus to effect a virus kill of at least 10 4 and to result in a retention of intact cell functionality and structure of greater than 80%. The present invention also is directed to a composition comprising human red blood cells suitable for transfusion at a concentration of ≧1×10 9 cells/ml and having all extracellular lipid enveloped and intracellular human pathogenic viruses in a non-infectious form.
Inventors
- 👤 Bernard Horowitz
- 👤 Jay E. Valinsky
- 👤 Nicholas E. Geacintov
- 👤 Bolanle Williams
- 👤 Shanti B. Rywkin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 20:59
CPC Classifications
A; A61; A61L; A61L2/00; A61L2/02; A61L2/08; A61L2/084; C; C12; C12N; C12N7/00; C12N7/04; A61K; A61K41/00; A61K41/0023; A61K41/0038; A61K41/0057; A61K41/0071; A61K41/10; A61K41/17; A61L2/10; C12N7/06; A61L2103/00; A61L2103/05; A61L2103/09; C12N2760/00; C12N2760/00011; C12N2760/20011; C12N2760/20211; C12N2760/20261; C12N2760/20263
Claims Analysis
Total Claims: 23
Claim 1
Independent Claim
103 words
A process for treating a blood cell-containing composition in order to inactivate any extracellular lipid enveloped human pathogenic virus and intracellular human pathogenic virus contained therein without incurring substantial disruption or inactivation of the cells, comprising contacting the cell-containing composition having ≧1×10 9 cells/ml with a virucidally effective amount of at least one photodynamically active compound having an absorption maximum of ≧630 nm, with light and with oxygen to substantially inactivate said virus if present therein and to effect a virus kill of at least 10 4 and to result in a retention of intact cell functionality and structure of greater than 80%.
Claim 2
Dependent Claim
103 words
A process for treating a blood cell-containing composition in order to inactivate any extracellular lipid enveloped human pathogenic virus and intracellular human pathogenic virus contained therein without incurring substantial disruption or inactivation of the cells, comprising contacting the cell-containing composition having ≧1×10 9 cells/ml with a virucidally effective amount of at least one photodynamically active compound having an absorption maximum of ≧630 nm, with light and with oxygen to substantially inactivate said virus if present therein and to effect a virus kill of at least 10 4 and to result in a retention of intact cell functionality and structure of greater than 80%.
Claim 3
Dependent Claim
11 words
A process according to claim 1, wherein intracellular virus is inactivated.
Claim 4
Dependent Claim
13 words
A process according to claim 1, wherein extracellular lipid enveloped virus is inactivated.
Claim 5
Dependent Claim
15 words
A process according to claim 1, wherein the cell-containing composition has 24 5×10 9 cells/ml
Claim 6
Dependent Claim
14 words
A process according to claim 1, wherein the cell-containing composition has ≧1×10 10 cells/ml.
Claim 7
Dependent Claim
14 words
A process according to claim 1, wherein the cell-containing composition has >4 mg/ml protein.
Claim 8
Dependent Claim
14 words
A process according to claim 1, wherein the cell-containing composition has >25 mg/ml protein.
Claim 9
Dependent Claim
16 words
A process according to clam 1, wherein the cell-containing composition has 50 to 60 mg/ml protein.
Claim 10
Dependent Claim
16 words
A process according to clam 1, wherein the cell-containing composition has 50 to 60 mg/ml protein.
Claim 11
Dependent Claim
12 words
A process according to claim 1, wherein the cells are unwashed cells.
Claim 12
Dependent Claim
19 words
A process according to claim 1, wherein the cells are unwashed and the cell-containing composition has ≧5×10 9 cells/ml.
Claim 13
Dependent Claim
13 words
A process according to claim 1, wherein the photoreactive compound is a phthalocyanine.
Claim 14
Dependent Claim
13 words
A process according to claim 11, wherein the phthalocyanine is an aluminum phthalocyanine.
Claim 15
Dependent Claim
14 words
A process according to claim 12, wherein the aluminum phthalocyanine is aluminum phthalocyanine chloride.
Claim 16
Dependent Claim
16 words
A process according to claim 12, wherein the phthalocyanine is a sulfonated form of aluminum phthalocyanine.
Claim 17
Dependent Claim
16 words
A process according to claim 14, wherein the phthalocyanine is AlPcS 2 or AlPcSp 4 .
Claim 18
Dependent Claim
19 words
A process according to claim 1, wherein the retention of intact cell functionality and structure is greater than 90%.
Claim 19
Dependent Claim
19 words
A process according to claim 1, wherein the retention of intact cell functionality and structure is greater than 98%.
Claim 20
Dependent Claim
17 words
A process according to claim 1, wherein at least 10 6 infectious units of virus are inactivated.
Claim 21
Dependent Claim
25 words
A process according to claim 1, further comprising storing the resultant treated cell-containing composition in liquid or frozen form, whereby reduced cell destruction is obtained.
Claim 22
Dependent Claim
14 words
A process according to claim 1, wherein the cell-containing composition contains red blood cells.
Claim 23
Dependent Claim
17 words
A process according to claim 20, wherein the red blood cells are treated in a blood bag.
References Cited (Backward Citations)
US4008136A
Cited
US4530924A
Cited
US4693981A
Cited
US4775625A
Cited
US4878891A
Cited
US4935498A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-06-09 | 1995-12-09 | 1996-06-09 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-06-09 | 1999-12-09 | 2000-06-09 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-06-09 | 2003-12-09 | 2004-06-09 | $7700.00 | Window Closed / Lapsed |